Zhuhai Meihua Medical Technology Co., Ltd, a leading Chinese provider of microbiology diagnostic instruments and reagents solutions, recently announced the completion of a Series B financing round of over CNY 100 million, which was jointly led by Stau Capital and Shanlan Capital, and followed by Zhuhai High-Tech Gold Investment and Qianhe Capital. Crowd Capital acted as the exclusive financial advisor for this round of financing. This round of financing will be mainly used for the company's product development investment, as well as to accelerate the marketing of its own brand and further expand the company's market share in the microbial diagnostic industry.

Founded in 2010, with the enterprise spirit of "focus on the smallest details and reputation of China", Meihua Medical focuses on the development and production of total solutions for clinical microbiology laboratories. In 2017, with the support of Series A financing from Beijing Beacon Medical Group and Orient Fuhai, the company has successfully developed a series of products covering all aspects of microbiology laboratories by gathering a team of excellent scientists from home and abroad, including MALDI-TOF mass spectrometry platform series, microbial identification/pharmacological sensitivity analyzer and supporting reagents series. Meihua Medical has successfully developed more than 30 diagnostic instruments and reagents in eight series, including MALDI-TOF mass spectrometry platform, microbial identification/pharmacology analyzer and reagents, fully automated blood culture instrument and reagents, reproductive infection identification/pharmacology series, microbial culture media series, microbial specimen pre-treatment series, microbial laboratory management and analysis system, microbial laboratory automation auxiliary equipment, etc., laying a solid foundation for completing the development of microbial laboratory automation pipeline.

Non-invasive Cancer Early Screening Company OneGene Completes Tens of Millions of CNY Series B Financing

Recently, Hangzhou OneGene Technology Co., Ltd. announced the completion of a Series B financing of tens of millions of CNY, invested by the listed company Chengda Pharmaceutical (301201). The funds in this round will be mainly used for the registration declaration of early screening products for intestinal cancer and the research and development of early screening for gastric cancer and liver cancer. Earlier the company received financing from Angel Bay Ventures, Far Eastern Information (300306) and other institutions.

Founded in 2014, OneGene is a leading non-invasive early cancer screening company. With the mission of "keeping everyone away from cancer earlier", OneGene uses its self-developed core technologies of tumor gene methylation and liquid biopsy to develop and provide cancer screening products with the four advantages of "non-invasive, accurate, early and universal" to help everyone win the war against cancer.